Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

New Lambton Heights, Australia Clinical Trials

A listing of New Lambton Heights, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (23) clinical trials

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage …

Phase

0.0 miles

Learn More »

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF. All patients will remain on their CF standard-of-care treatments over the trial duration. The goal for the treatment with LAU-7b in CF is to …

Phase

0.0 miles

Learn More »

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Study details: Participants will be allocated to either experimental or control group in a 2:1 ratio by chance (randomly). Patients assigned to the experimental group will receive a course of nivolumab via intravenous infusion (240 mg on days 1 and 15 every 28 days for cycles 1-4; then 480 mg …

Phase

0.0 miles

Learn More »

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

This is a randomized, double-blind, parallel group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of CNM-Au8 in stable RRMS patients who have Chronic Optic Neuropathy (residual deficits of conduction velocity in the visual pathway) evidence by low contrast letter acuity deficits at Screening. Patients will be screened over a …

Phase

0.0 miles

Learn More »

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

This study enrolls participants with high risk NMIBC FGFR mutations or fusions. Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor with demonstrated clinical activity in participants with solid tumors, including urothelial carcinoma, with alterations in the FGFR pathway. In Cohort 1, participants will be randomized to erdafitinib …

Phase

0.0 miles

Learn More »

NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction

After someone has a MI, their heart 'remodels', which means that it changes in size and shape. This damage can lead to it being weaker and less efficient, and ultimately to major heart problems. There are some drugs currently available which help prevent remodelling and are used for treatment post-MI. …

Phase

0.93 miles

Learn More »

Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients

This study is designed to investigate in a prospective, randomised fashion whether a single intravenous dose of rituximab (375 mg/m2) given two weeks prior to transplant, in addition to standard therapy, will allow sensitised renal transplant subjects to achieve a negative CDC crossmatch and thereby proceed to live donor transplantation. …

Phase

0.93 miles

Learn More »

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

PROTOCOL SYNOPSIS Background Despite highly active current treatment for metastatic gastrointestinal stromal tumour (GIST) with the use of imatinib, most people will ultimately relapse and die of multifocal metastatic disease. Using an alternating regimen of imatinib and regorafenib with brief drug free intervals may allow tumour stem cells to re-enter …

Phase

1.5 miles

Learn More »

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma

Renal cell carcinoma (RCC) is the 9th most common cancer in Australia, the 10th most common cancer in Western populations1. Approximately 75% of kidney cancers are clear-cell renal cell carcinomas (ccRCC). Current treatments for metastatic ccRCC include VEGFR tyrosine kinase inhibitors (TKIs) and mTOR inhibitors and while many patients benefit …

Phase

2.47 miles

Learn More »

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

MDS is an insidious and largely incurable haematological malignancy that increasingly impacts on the well-being of our ageing population, and one for which there has been no significant therapeutic advance since the introduction of injectable AZA (Vidaza) over a decade ago. Furthermore, the basis for the effectiveness of Vidaza or …

Phase

2.47 miles

Learn More »